Seizure Clinical Trial - Study of Predictors of Response to Anti Epilepsy

Status Terminated

Clinical Trial Summary

Pharmacoresistant epilepsy remains around 30% despite the development of 25 anti epileptic drugs. Of course, this can be explained by pharmacoresistant epileptic brain diseases, as exemplified by some genetic diseases. However, the lack of specific guidelines for the choice of the anti epileptic drugs (apart from generalized and partial epilepsy) and the very large number of drugs with different and sometimes complex metabolism are challenges for neurologists. Among the 30 % of pharmacoresistant epilepsy, there is a part related to pharmacokinetic drawbacks that could be overcome with a more rigorous approach (i.e. dosage and pharmacogenetics tools). Moreover, the new anti epileptic drugs have metabolism more unrelated with the cytochrome P450 and less generalised adverse events. However, their metabolism could be more complexe (i.e. the less known Uridine 5'-diphospho-glucuronyltransferase (UGT) pathway) and bring more insidious neurological adverse events (i.e. depression, anxiety exacerbation, cognitive disorders worsening) which could largely impede the observance and the quality of life even if the number of seizure is reduced or not. The goal is to determine the predictive and the modulating factors of pharmacoresistance with a global analysis (i.e. whatever the anti epileptic drugs) and with a specific analysis (drug by drug) from a cohort of 1000 patients.

Clinical Trial Description

The goal is to determine the predictive and the modulating factors of pharmacoresistance with a global analysis (i.e. whatever the anti epileptic drugs) and with a specific analysis (drug by drug with their specific metabolism pathways) from a cohort of 1000 patients. The response to the antiepileptic drugs modification will be analyse 3 months after the modification, with the analysis of the number of seizures, the quality of life, the Clinical Global Impression, the adverse events, the systematic dosage of all the molecules (residual concentration just before the taken) and the pharmacogenetic analysis of the main metabolism pathways and the main pharmacodynamic targets. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02883712
Study type	Observational
Source	University Hospital, Lille
Contact
Status	Terminated
Phase
Start date	May 21, 2013
Completion date	January 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00021866` - Developmental Effects On Children Of Women Who Take Antiepileptic Drugs During Pregnancy	N/A
Completed	`NCT01417507` - Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery	N/A
Completed	`NCT01123746` - Utility of Laboratory Testing for Children With Seizure in Emergency Department	N/A
Completed	`NCT02926703` - Lactate Compared to Creatine Kinase as Diagnostic Marker in Generalized Epileptic Seizure	N/A
Completed	`NCT01796574` - Ketogenic Diet for Refractory Status Epilepticus	N/A
Not yet recruiting	`NCT01436695` - Safety and Feasibility of Using Epicall for Monitoring Pre-seizure Biomarkers	N/A
Recruiting	`NCT05746624` - Procedural Motor Memory in Long COVID-19	N/A
Completed	`NCT00880204` - Evaluation of Essential Surgical Skills-Emergency Maternal and Child Health Training	N/A
Enrolling by invitation	`NCT02694094` - Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy
Completed	`NCT02426047` - Medium Chain Triglycerides as an Adjunct to the Modified Atkins Diet for Women With Catamenial Epilepsy	N/A
Completed	`NCT01744301` - Acid Suppressing Drug Seizure Epidemiology Study	N/A
Completed	`NCT01834482` - Modified Atkins Diet Plus KetoCal for Adult Epilepsy	N/A
Completed	`NCT00946751` - To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions	Phase 1
Completed	`NCT01694524` - Nervous System Infections Among Patients With Febrile Seizure	N/A
Terminated	`NCT01910129` - Neurostimulation to the Vagus Nerve for the Reduction in Frequency of Seizures Associated With Epilepsy	N/A
Completed	`NCT00298532` - OPALS Pediatric Study	N/A
Completed	`NCT01982812` - A Dose-Escalation, Safety and Feasibility Study of Enteral LVT for Seizure Control in Pediatric CM	Phase 2
Completed	`NCT01660672` - Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria	Phase 1/Phase 2
Completed	`NCT00285285` - Point of Care Device Use in the Pediatric Emergency Department	N/A
Completed	`NCT01801072` - Seizure Prophylaxis in Aneurysm Repair	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of Predictors of Response to Anti Epilepsy in Epilepsy — RESISTANT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms